Genomictree Inc.
228760
Peringkat dalam Saham
#19188
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Harga Saham
$6.58
Kapitalisasi Pasar
$161.41M
Perubahan (1 hari)
-0.63%
Perubahan (1 tahun)
-50.29%
Negara
KR
Perdagangan Genomictree Inc. (228760)
Kategori
Healthcare
Laba untuk Genomictree Inc. (228760)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari Genomictree Inc., laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Genomictree Inc. dari 2026 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
